Belite Bio, Inc

NASDAQ:BLTE

Biotechnology

Healthcare
$156.23 +0.31%

+$0.46 today

Market cap
$6.29B
Beta
-1.24
P/E (TTM)
-65.9
EPS (TTM)
-$2.26
52W Low $56.10High $200.00

Volume 0.09M

Average 0.17M

BLTE Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Belite Bio, IncNASDAQ: BLTE

Operating Income · Q3 FY2026 · quarter ended Sep 2026

Operating income remains negative

Q3 FY2026 operating income was -$36.91M, compared with -$23.02M a year earlier. Trailing-twelve-month operating income was -$132.58M.

Context

  • Operating income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -110.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$36.91M-5.7% QoQ
Last fiscal yearDec 2025
-$84.21M-110.5% YoY
LTMSep 2026
-$132.58M-96.2% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-60.4%+100.0%+160.4 pp
1 year-110.5%+100.0%+210.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(84.21M) USD
Year-over-year change
-110.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How BLTE compares with its peers on the latest reported figures

  • BLTE's LTM Sep 2026 operating income of -$132.58M is the 4th highest of the 6 companies compared; the peer median is -$66.25M.
  • Its year-over-year change of -96.2% is the lowest of 6, against a peer median of -12.6%.
BLTE Competitors Peer median
Operating Income for BLTE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRDOpus Genetics, Inc.LTM Mar 2026-$43.03M +33.1%—359.1%
KLRSKalaris Therapeutics IncLTM Mar 2026-$47.63M +33.8%——
OCGNOcugen, Inc.LTM Mar 2026-$66.25M -16.1%—1483.9%
BLTEBelite Bio, IncLTM Sep 2026-$132.58M -96.2%——
KODKodiak Sciences Inc.LTM Sep 2026-$251.17M -12.6%——
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$281.82M -74.6%—3700.9%
Peer median (excluding BLTE) -$66.25M-12.6%—1483.9%

Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development7.42M8.87M24.84M29.94M45.38M
Selling, General & Admin2.38M3.95M6.82M10.06M38.83M
Operating Expenses9.8M12.82M31.67M40M84.21M
Depreciation & Amortization30K198K399K449K464K
EBITDA(9.64M)(12.43M)(31.2M)(35.67M)(77.15M)
EBITDA Margin—————
Operating Income(9.8M)(12.82M)(31.67M)(40M)(84.21M)
Operating Margin—————
Interest Income5K23K74K3.74M0
Interest Expense016K25K20K0
Other Income / Expenses131K173K45K3.86M6.6M
Income Before Tax(9.67M)(12.65M)(31.62M)(36.14M)(77.61M)
Pre-Tax Margin—————
Income Tax Expense009K6K0
Net Income(9.67M)(12.65M)(31.63M)(36.14M)(77.61M)
Net Margin—————
EPS (Basic)(0.40)(0.63)(1.19)(1.18)(2.31)
EPS (Diluted)(0.40)(0.63)(1.19)(1.18)(2.31)
Weighted Avg Shares24.1M19.98M26.59M30.54M33.54M
Weighted Avg Shares (Diluted)24.1M19.98M26.59M30.54M33.54M

Belite Bio, Inc

NASDAQ:BLTE

Intrinsic Alpha fair value

Locked

Current Price

$156.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.